Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
AKTX 
Akari Therapeutics PLC (AKTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: AKTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.53
1 Year Target Price $4.53
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 25.22% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.96M USD | Price to earnings Ratio - | 1Y Target Price 4.53 |
Price to earnings Ratio - | 1Y Target Price 4.53 | ||
Volume (30-day avg) 1 | Beta 0.26 | 52 Weeks Range 0.22 - 1.73 | Updated Date 12/6/2025 |
52 Weeks Range 0.22 - 1.73 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.56% | Return on Equity (TTM) -112.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9725899 | Price to Sales(TTM) - |
Enterprise Value 9725899 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.06 | Shares Outstanding 32614731 | Shares Floating 15835104195 |
Shares Outstanding 32614731 | Shares Floating 15835104195 | ||
Percent Insiders 31.48 | Percent Institutions 3.75 |
Upturn AI SWOT
Akari Therapeutics PLC
Company Overview
History and Background
Akari Therapeutics PLC is a biopharmaceutical company focused on developing therapies for rare and severe autoimmune diseases. The company was incorporated in 2017. A significant milestone was its listing on the Nasdaq Capital Market in 2021. Akari has evolved by advancing its lead product candidate through clinical trials and establishing a pipeline of potential treatments.
Core Business Areas
- Autoimmune Disease Therapeutics: Akari Therapeutics PLC's primary focus is on developing treatments for rare and severe autoimmune diseases. Their core strategy revolves around identifying and advancing novel therapeutic candidates through the clinical development process.
Leadership and Structure
Akari Therapeutics PLC is led by a management team with expertise in drug development and the biopharmaceutical industry. The organizational structure is typical of a clinical-stage biopharmaceutical company, with functions dedicated to research and development, clinical operations, regulatory affairs, and corporate operations.
Top Products and Market Share
Key Offerings
- AkariX (Nomacopan): Nomacopan is Akari Therapeutics PLC's lead product candidate, a dual inhibitor of complement C5 and LTB4. It is being developed for the treatment of conditions such as bullous pemphigoid (BP), atypical hemolytic uremic syndrome (aHUS), and other rare complement-mediated diseases. Market share data is not yet applicable as the product is in clinical development. Key competitors in the broader autoimmune disease space include companies developing biologics and small molecules for inflammatory conditions.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in the rare and autoimmune disease space, is characterized by high unmet medical needs, significant R&D investment, stringent regulatory pathways, and the potential for substantial therapeutic and commercial impact. The market is driven by scientific innovation, patient advocacy, and evolving healthcare reimbursement landscapes.
Positioning
Akari Therapeutics PLC is positioned as a developer of novel therapies for underserved patient populations with rare and severe autoimmune diseases. Their focus on specific complement-mediated pathways offers a differentiated approach. Their competitive advantage lies in the unique mechanism of action of their lead candidate and their targeted development strategy.
Total Addressable Market (TAM)
The TAM for treatments targeting rare autoimmune diseases is significant and growing, driven by increasing diagnoses and the demand for more effective therapies. Akari Therapeutics PLC is positioned to address specific sub-segments within this larger TAM based on the indications for which Nomacopan is being developed.
Upturn SWOT Analysis
Strengths
- Novel therapeutic candidate (Nomacopan) with a unique dual mechanism of action.
- Focus on rare and severe autoimmune diseases with high unmet medical needs.
- Experienced management team with a track record in drug development.
- Potential for orphan drug designation and accelerated regulatory pathways.
Weaknesses
- Clinical-stage company with no approved products, hence no revenue generation from sales.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Significant capital requirements for ongoing R&D and clinical development.
- Limited historical financial data due to its early-stage nature.
Opportunities
- Advancement of Nomacopan through Phase 3 clinical trials and potential regulatory submission.
- Expansion of the pipeline with additional therapeutic candidates.
- Potential for strategic partnerships or collaborations with larger pharmaceutical companies.
- Growing market demand for innovative treatments for rare diseases.
Threats
- Failure to demonstrate efficacy or safety in clinical trials.
- Regulatory hurdles and delays in drug approval.
- Competition from other companies developing similar or alternative therapies.
- Challenges in securing sufficient funding for ongoing operations and development.
Competitors and Market Share
Key Competitors
- UCB SA (UCB)
- Alexion Pharmaceuticals (part of AstraZeneca) (AZN)
- Horizon Therapeutics plc (HZNP) (now part of Amgen)
- ChemoCentryx, Inc. (CCXI) (now part of Amgen)
Competitive Landscape
Akari Therapeutics PLC faces competition from established biopharmaceutical companies with broad portfolios in immunology and rare diseases, as well as other smaller biotech firms developing novel therapies. Akari's competitive advantage lies in the specific mechanism of action of Nomacopan, targeting both complement and LTB4, potentially offering a unique therapeutic profile for certain indications.
Growth Trajectory and Initiatives
Historical Growth: Akari Therapeutics PLC's historical growth has been characterized by its progression through preclinical and early clinical development stages. The company has focused on building its R&D capabilities and advancing its lead candidate.
Future Projections: Future growth projections for Akari Therapeutics PLC are contingent upon the successful completion of its clinical trials, regulatory approvals, and potential commercialization of its lead product, Nomacopan. Analyst estimates would likely focus on potential peak sales if approved and the valuation multiples associated with similar successful biopharmaceutical companies.
Recent Initiatives: Recent initiatives likely include advancing Nomacopan into later-stage clinical trials, pursuing orphan drug designations for key indications, and potentially seeking strategic partnerships or collaborations to accelerate development and commercialization.
Summary
Akari Therapeutics PLC is a clinical-stage biopharmaceutical company with a promising lead candidate, Nomacopan, targeting rare autoimmune diseases. Its strength lies in its novel mechanism of action and focus on unmet medical needs. However, the company faces significant risks associated with clinical trial outcomes, regulatory approvals, and the need for substantial capital. Continuous innovation and successful execution of its development pipeline are crucial for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., 10-K, 10-Q)
- Financial News and Analysis Websites
- Industry Research Reports
- Company Investor Relations
Disclaimers:
This JSON output is generated for informational purposes only and does not constitute financial or investment advice. The information provided is based on publicly available data and may not be exhaustive or up-to-date. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akari Therapeutics PLC
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2015-09-21 | CEO, President & Director Mr. Abizer Gaslightwala | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.akaritx.com |
Full time employees 8 | Website https://www.akaritx.com | ||
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.